Tirzepatide injections are once-weekly subcutaneous doses, meaning the medicine goes into the fatty layer beneath the skin rather than into muscle or a vein. The injection may come in a prefilled single-dose pen, a four-dose KwikPen, a brand vial, or a compounded vial paired with a syringe. The device changes the handling, not the basic schedule. The prescriber and dispensing pharmacy determine the exact dose, concentration, equipment, and instructions.
What tirzepatide injections are
Tirzepatide is a peptide medication that activates GIP and GLP-1 receptors. A subcutaneous injection places medicine in the fatty tissue beneath the skin, from which it is absorbed over time. It is not an intravenous infusion and is not intended to reach muscle.
The weekly rhythm comes from the molecule's long pharmacokinetics, not from the device. A population analysis pooling 39,644 measurements from 5,802 participants calculated a mean half-life of 5.4 days and 1.7-fold accumulation with repeated dosing (Schneck and Urva, CPT: Pharmacometrics & Systems Pharmacology, 2024). An earlier phase 1 study likewise measured a half-life of about five days during once-weekly subcutaneous dosing (Furihata et al., Diabetes, Obesity and Metabolism, 2022). That slow decline maintains exposure across the week; it does not mean the medicine disappears on day five. The fuller timeline is covered in how long tirzepatide stays in the system.
Pen, KwikPen, and vial formats are not interchangeable
As of September 2026, the February 2026 Zepbound prescribing information and January 2026 Mounjaro prescribing information list several presentations. They contain tirzepatide, but the preparation steps and disposal are specific to the presentation.
| Presentation | What it holds | What changes on injection day |
|---|---|---|
| Prefilled single-dose pen | One fixed dose | The needle is built into the disposable device |
| Single-patient-use KwikPen | Four fixed weekly doses | A compatible new pen needle is attached for each dose |
| Zepbound single-dose vial | One fixed brand dose | The labeled volume is drawn with a separate syringe |
| Compounded vial | A patient-specific prescription | Concentration, volume markings, storage, and supplied syringe may differ by pharmacy |
With a compounded vial, the number of syringe units is not a universal translation of milligrams. It depends on the concentration printed on that vial. A brand pen's clicks, a brand vial's volume, and another pharmacy's syringe directions cannot be carried over to it. Some vial presentations also require preparation while others arrive as liquid; how peptide reconstitution works explains the distinction, but the pharmacy's directions control.
Mounjaro and Zepbound are brand-name products. Tirzepatide through Promise is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket review for safety, effectiveness, or quality. At Promise, a licensed provider reviews every request and not everyone qualifies; whether a compounded formulation is appropriate is a decision between the patient and the reviewing provider.
What a weekly injection day is like
The practical routine is short, but it starts with identifying the exact presentation. The label is checked against the prescription, the medicine is inspected, and the manufacturer or pharmacy instructions are followed for that device. A single-dose pen, a KwikPen, and a vial-and-syringe setup do not share one universal sequence. Food timing is not part of the Zepbound label's administration rule; it permits dosing at any time of day, with or without food.
Vial formats usually use a fine, short insulin-style needle. Published subcutaneous diabetes-injection research gives a sense of the norm: 31- or 32-gauge needles measuring 4, 6, or 8 mm were compared in a randomized crossover study, with the short formats producing comparable insulin exposure (Hirose et al., Journal of Diabetes Investigation, 2013). That is context, not a tirzepatide equipment prescription. The pharmacy chooses a syringe and needle that match the prescribed volume; the supplied or specifically recommended equipment is the relevant equipment.
The current brand labels name the abdomen, thigh, and back of the upper arm as injection areas and call for a different spot each week, even when the same general area is reused. Rotation helps avoid repeatedly irritating one small patch of tissue. Where to inject tirzepatide covers the site question in detail rather than turning this overview into a technique guide.
Semaglutide is also commonly given as a weekly subcutaneous injection, but it is a different molecule with different prescriptions and device instructions. The two medications, pens, and vial directions are not interchangeable.
What the label says about a missed week
The February 2026 Zepbound label gives a precise rule: a missed dose may be administered within four days, or 96 hours, of the scheduled dose. Once more than four days have passed, the label says that dose is skipped and the next one falls on the usual day. It also requires at least three days, or 72 hours, between two doses when the weekly day changes.
That rule describes the branded label. Illness, a long interruption, dose escalation, or uncertainty about how much entered the skin calls for the prescriber rather than a catch-up calculation. The tirzepatide dosage schedule explains how clinicians make those decisions without turning the label into a self-directed protocol.
Needles and pens need a disposal plan
Used syringes and detachable pen needles go directly into a sharps container, not loose into household trash or recycling. The FDA recommends an FDA-cleared sharps container. When one is unavailable, its guidance describes a heavy-duty plastic alternative that stays upright and has a tight, puncture-resistant lid. Final disposal follows local rules, which vary by community.
A single-dose pen also contains a needle after use, while a KwikPen has a removable needle and a pen body used for four doses. The product instructions say which parts enter a sharps container and when the multi-dose device is discarded. A small travel sharps container makes the same routine possible away from home.
The right routine follows the specific prescription
Before the first injection, the useful questions are concrete: Which presentation was dispensed? What concentration is on the vial? Which syringe line corresponds to the prescribed volume? How should that specific product be stored? What should happen if a dose is late or a device seems incomplete?
Those answers should come from the reviewing provider, dispensing pharmacy, and instructions packaged with the product. A calm weekly routine is easier to build when the device, the label, and the clinical plan all agree.